Lisa Rhoads is the Founder and Managing Partner of a Private Equity Healthcare Company. In this role, she drives the firm’s healthcare private equity investment strategy as well as helps provides capital advisory to healthcare business across the capital structure.
Previously, Lisa was a Managing Director with the Easton Capital Group, a venture capital firm focused on the healthcare sector. She led sourcing, due diligence, and the structuring of investments, while participating in fundraising activities for the firm. She also served on the Board of numerous portfolio companies, assisting with strategy, product development, and mergers & acquisitions, and played an instrumental role in delivering a 5X increase in the valuation of key investments.
Lisa is known throughout the industry for her understanding of the emerging markets. She has structured innovative technology licensing agreements with pharmaceutical and private equity partners in both China and Brazil. These deals are projected to generate $15M in incremental revenues for the portfolio firms of Easton Capital over the course of next 3 to 5 years.
Prior to joining Easton Capital, Lisa served as Chief Administrative Officer and Senior Vice President of Intellectual Property at Celtic Pharma Management, a venture capital firm focused on the biotechnology and pharmaceutical industries. She was a founding member of the firm, opening the Bermuda office, leasing the New York City office space, and establishing the intellectual property function. She also served on the Boards of numerous portfolio companies.
Lisa’s previous experience includes serving as Director of Consumer Marketing for the U.S. Pharmaceutical business of Bristol-Myers Squibb, and as Consumer Strategist at Zeneca Pharmaceuticals.
She holds a Master of Business Administration from the Wharton School of the University of Pennsylvania, and a Bachelor of Music from the Curtis Institute of Music. She currently teaches entrepreneurship and serves on the boards the Turtle Bay Music School in addition to Network 20/20.
